Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
7,341 total articles
Century Aluminum CO (NASDAQ:CENX) Chief Financial Officer Peter A. Trpkovski sold 16,739 shares of company stock on March 25, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The sales, executed in several trades at prices between $50.50 and $50.64, totaled $845,486. After the transactions, Trpkovski holds 64,125 shar…
Ouster Inc.'s Chief Technology Officer, Mark Frichtl, sold 40,000 shares of the company's common stock on March 25, 2026, under a pre-established Rule 10b5-1 trading plan and simultaneously exercised 40,000 options. The transactions followed a quarter in which Ouster beat consensus revenue and margin estimates and prompted positive analyst reaction…
Star Equity Holdings CEO Jeffrey E. Eberwein sold 15,278 shares of Series A Preferred Stock across three trades between March 25 and March 27, 2026, raising roughly $152,185. The company has also completed a sale-leaseback, launched a $2 million repurchase program under Rule 10b5-1, updated executive compensation terms and received an unsolicited i…
Ollie’s Bargain Outlet Executive Chairman John W. Swygert executed a planned sale of 3,898 shares on March 27, 2026, netting $348,481, while earlier converting restricted stock units led to an additional disposition tied to tax obligations. The transactions occurred as the stock traded near its 52-week low and after the company reported modestly st…
ARM Holdings CFO Jason Child sold 21,280 ordinary shares on March 25, 2026, for $3.1 million under a pre-arranged Rule 10b5-1 plan. The transaction leaves Child with 174,706 shares. The sale occurred as ARM stock traded below the sale price and after the company reported a 26% jump in Q3 2025 revenue driven by artificial intelligence-related growth…
Marc Crossman, Playboy, Inc.'s CFO and COO, disposed of 104,035 shares on March 25, 2026 to cover tax obligations tied to the settlement of restricted stock units. The shares were sold between $1.645 and $1.745 per share for total gross proceeds of $172,843. Following the sale, Crossman retains 769,759 shares directly; his wife holds 19,608 shares …
Kimberly Bullock Gatling, a director at Culp Inc (CULP), purchased 1,812 shares on March 26, 2026, at $2.97 per share for a total of $5,381. The purchase occurred with the stock trading near its 52-week low and shortly after the company reported third-quarter fiscal 2026 results that missed analyst expectations on both earnings and revenue.
American Healthcare REIT executive Mark E. Foster carried out share sales and conversions on March 25, 2026 under a previously adopted Rule 10b5-1 plan and tax-covering actions, while the company reported fourth-quarter 2025 results that surpassed analyst expectations and put in place an at-the-market equity offering allowing for up to $1.75 billio…
Zevia PBC Chief Financial Officer Satya Girish sold 41,662 shares of Class A Common Stock on March 25, 2026 to satisfy tax obligations tied to restricted stock units, while the company reported mixed fourth-quarter 2025 results and announced a multi-year partnership with artist Cardi B. The insider sale occurred as the stock traded near its 52-week…
United Therapeutics Chairperson and CEO Martine Rothblatt executed an option exercise for 9,500 shares and sold those shares the same day under a pre-arranged 10b5-1 plan, generating roughly $5.09 million in proceeds. The transactions occurred March 26, 2026. Separately, the company announced positive phase 3 TETON-2 results for nebulized Tyvaso in…
Phreesia Chief Financial Officer Balaji Gandhi sold 3,829 shares of common stock on March 25, 2026, at a weighted average price of $11.2635, generating $43,127 to satisfy tax withholding on restricted stock units. The transaction coincides with a refinancing of the companys bridge loan into a $275 million senior secured revolving credit facility a…
Ryan Goepel, President and Chief Financial Officer of Global Crossing Airlines Group Inc (JETMF), executed three separate sales of common stock totaling 158,929 shares between February 20, 2026, and March 23, 2026, generating proceeds of $73,259. The transactions were reported on a Form 4 filed with the Securities and Exchange Commission. After the…
United Therapeutics Chief Financial Officer and Treasurer Edgemond James sold $5.36 million of company stock on March 26, 2026, while exercising stock options for 10,000 shares the same day. The trades were executed under a Rule 10b5-1 plan. The company has also announced a $2 billion repurchase program and reported that its phase 3 TETON-2 study o…
Tyra Biosciences director Gilla Kaplan executed a series of option exercises and subsequent stock sales on March 25-26, 2026, realizing proceeds of roughly $2.54 million while retaining a stake in the company. The transactions coincide with a recent block sale of 4,000,000 shares that raised $126 million for the company and with sustained analyst s…
Kimberly D. Campos, who serves as Chief Information Officer and Chief Accounting Officer at Universal Insurance Holdings, sold 879 shares on March 26, 2026, realizing $29,745. The company recently reported fourth-quarter 2025 results that included an EPS of $2.17, materially above analyst expectations, while revenue came in marginally below forecas…
Okta Chief Revenue Officer Jonathan James Addison sold 23,304 shares of Class A common stock on March 25, 2026, for about $1.8 million under a pre-established Rule 10b5-1 plan. The trades took place at prices between $77.1011 and $78.653 per share. The stock's market quote sits at $73.21, near a 52-week low of $68.77, while InvestingPro’s Fair Valu…
Sean P. Downes, Executive Chairman of Universal Insurance Holdings (NASDAQ: UVE), sold 20,000 shares on March 25, 2026, for $692,072 at a weighted average price of $34.6036. The transaction occurred as the stock trades at a P/E of 5.34 and has returned 53% over the past year. Universal Insurance reported fourth-quarter 2025 EPS of $2.17, well ahead…
Karen Sykes, President and CMO of DD'S DISCOUNTS at Ross Stores, sold 5,506 shares on March 25, 2026, for $213.4006 per share, a transaction valued at $1,174,983. The sale occurred while the share price trades close to a 52-week high and after the company reported better-than-expected fourth-quarter fiscal 2025 results and signalled an aggressive s…
Cardinal Infrastructure Group Inc. (NASDAQ: CDNL) director Zelman Ivy purchased 6,921 shares on March 26, 2026, at a weighted average price of $36.33, a transaction totaling $251,439. The trade occurred as the stock trades near its 52-week high and follows robust quarterly revenue growth and a regional leadership appointment.
BKV Corp Chief Financial Officer David Tameron sold 7,300 shares of common stock on March 27, 2026, in multiple transactions that averaged $29.71 per share. The sale, executed under a pre-established Rule 10b5-1 trading plan, raised $216,918 and leaves Tameron with 61,925 shares. The transaction comes as BKV reports solid fourth-quarter results, an…
Director Charles Thomas McMillen sold 30,000 shares of Castellum, Inc. (OTC:CTM) on March 25, 2026, for $21,129, according to a Form 4 filing. The transaction follows a recent share-price decline and leaves McMillen with 231,015 shares. Separately, the company has retired $400,000 of debt, increased cash to over $14 million, and its subsidiary Spec…
Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff sold 26,198 shares on March 25, 2026, generating about $1.3 million in proceeds under a Rule 10b5-1 plan. The company recently secured FDA approval for Lifyorli and received an analyst upgrade, even as its stock has fallen and a securities class action was filed.
Arteris, Inc. President and CEO K. Charles Janac executed two stock sales on March 25 and March 26, 2026, disposing of a combined 40,000 shares for about $731,623. The transactions followed a period of notable share-price appreciation. The company also reported fourth-quarter 2025 results that exceeded consensus estimates for both revenue and earni…
A Tecogen director purchased 10,000 shares on March 27, 2026, increasing her holdings to 260,416 shares. The trade occurred as the stock was trading near $2.57 and follows a quarter in which Tecogen missed earnings and revenue estimates. Market research notes suggest the stock may be undervalued and the company carries more cash than debt.
Legend Biotech Chief Executive Officer Huang Ying sold 9,936 ordinary shares on March 25, 2026, for roughly $87,138, according to an SEC Form 4. The sale occurred as the stock traded near a 52-week low, even after the company reported a revenue beat for the fourth quarter and full-year 2025 driven by Carvykti. Analysts issued a range of price targe…
